Open an account

USANA Health Sciences

USNA · NYSE

$14.72−$0.17 (−1.14%)TodayMarket closed ·
Prev close $14.89

USNA analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Apr 10, 2025

Bull case

Usana Health Sciences Inc. has projected a slight improvement in organic sales for 2025, with an upward revision of its growth forecast from -6% to -5%, reflecting positive momentum in regions such as Greater China and the Americas. The company benefited from a lower-than-expected tax rate, which contributed an additional $0.1 to earnings per share, while ongoing reductions in material costs and favorable market mix dynamics enhanced year-over-year financial performance. Furthermore, the growth expectations for Usana's Hiya direct-to-consumer segment have increased significantly, with management anticipating a 41%-55% growth rate, indicating strong prospects for future revenue expansion.

Bear case

Usana Health Sciences, Inc. reported a 6.2% decline in third-quarter sales to $200 million, falling short of the consensus expectation of $206 million, indicating a challenging market environment. Despite an earnings per share (EPS) beat of $0.56 owing to lower SG&A expenses, the company has reduced its EPS guidance for 2024 to $2.45, highlighting a cautious outlook amid ongoing macroeconomic pressures that are suppressing consumer spending. The anticipated flattening of sales growth has been pushed out to 2026, and potential risks related to economic downturns raise concerns about the company's future profitability and cash flow.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.